fosfomycin tromethamine / Generic mfg. - LARVOL DELTA

Rare case of urinary tract infection caused by Cedecea lapagei in a 93-year-old patient in southern Italy. (PubMed, Infez Med) - "The patient was successfully treated with ciprofloxacin and fosfomycin, achieving clinical and microbiological healing. Incorporating rare pathogens into differential diagnoses, particularly for elderly patients with recurrent UTIs, could improve patient outcomes significantly. Finally, these findings expand the limited existing data on Cedecea lapagei infections, providing valuable insights into more precise diagnostic methodologies and tailored therapeutic approaches."

Journal • Infectious Disease • Nephrology

Tackling multidrug-resistant gram-negative infections in Children globally: current therapeutic options and perspectives. (PubMed, Expert Opin Pharmacother) - "New β-lactam antibiotics, alone or in combination with β-lactamase inhibitors - such as ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, imipenem-cilastatin-relebactam, and cefiderocol - have emerged as preferred options for treating carbapenem-resistant and difficult-to-treat Gram-negative infections. Therapy should be guided by pathogen identification and resistance mechanisms, as susceptibility profiles vary widely based on the resistance-mechanism. Older agents like colistin, fosfomycin, nitrofurantoin, and aminoglycosides remain important, particularly in resource-limited settings, despite concerns over toxicity and safety."

Journal • Review • Infectious Disease • Pediatrics

Fosfomycin resistance determinants in Escherichia coli isolates of human and animal origin from Iran. (PubMed, Mol Biol Rep) - "Emergence of fosfomycin resistance among studied isolates was mainly attributed to plasmid genes coding for fosfomycin modifying enzymes. The similarity in fosfomycin resistance determinants among clonally diverse E. coli isolates of human and animals indicates a possible cross-sectoral dissemination of fos genes by epidemic plasmids between bacterial isolates of clinical settings and those from animals."

Journal • FOS

TREAT-GNB: Optimising TREATment for Severe Gram-Negative Bacterial Infections (clinicaltrials.gov) - P4 | N=600 | Recruiting | Sponsor: National University of Singapore

New P4 trial • Infectious Disease • Pneumonia • Respiratory Diseases

Gepotidacin: A Novel Antibiotic for the Treatment of Uncomplicated Urinary Tract Infections. (PubMed, Ann Pharmacother) - "Gepotidacin is an antibiotic with a novel mechanism of action that is efficacious in the treatment of women with uUTIs caused by common uropathogens, including resistant strains."

Journal • Review • Infectious Disease • Nephrology

Genomic insights into a colonization-infection progression by a carbapenemase-producing Klebsiella quasipneumoniae K1 serotype. (PubMed, J Glob Antimicrob Resist) - "These results revealed the potential of a colonization scenario by a KPC-2-producing K1 K. quasipneumoniae in progressing to an infectious process in an impaired patient, which may help programs intended to combat the antimicrobial resistance."

Journal • Infectious Disease • Pneumonia

Macrococcus capreoli sp. nov., a new fosfomycin resistant species isolated from feces and nasal swabs of deer. (PubMed, Syst Appl Microbiol) - "is proposed. The type strain is TMW 2.2395T = DSM 113939T = LMG 32618T."

Journal • Infectious Disease • CAT

Molecular characterization of carbapenem resistance mechanisms and phenotypic correlations in clinical Klebsiella pneumoniae isolates from Ningbo, China. (PubMed, Front Microbiol) - "The tested agents included: (1) basic antimicrobials (tigecycline, polymyxin B, ceftazidime-avibactam); and (2) combination therapy candidates (ertapenem, imipenem, levofloxacin, piperacillin-tazobactam, ceftriaxone, cefepime, trimethoprim-sulfamethoxazole, fosfomycin, amikacin, aztreonam, chloramphenicol, amoxicillin-clavulanate, ceftazidime)...The 150 strains of CRKP exhibit high resistance rates to various conventional drugs; The sensitivity rates to tigecycline, polymyxin B, and ceftazidime-avibactam were 98.7, 98.0, and 68%, respectively; Conversely, the sensitivity rates to fosfomycin, amikacin, and chloramphenicol were 72.0, 40.0, and 16.7%, respectively; The main proportions of carbapemen genes producing in CRKP are as follows: KPC-2 (61.3%), NDM-5 (14.7%), IMP-4 (8.0%), OXA-232 (6.0%), and OXA-181 (1.3%); The main proportions of β-lactamase resistance genes are as follows: CTX-M-1 (13.33%), CTX-M-3 (25.33%), CTX-M-9 (17.33%), CTX-M-14 (34.67%), SHV-1 (26.66%),..."

Journal • Infectious Disease • Pneumonia

Comparative Evaluation of Conventional Methods and Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) for Uropathogen Identification in Catheter-Associated Urinary Tract Infections in ICU Patients. (PubMed, Cureus) - "High resistance was observed against fluoroquinolones and cephalosporins, while fosfomycin and linezolid remained effective against Enterococcus spp. Conclusion MALDI-TOF MS enhances the speed and accuracy of pathogen identification, making it a valuable tool for managing CAUTI cases. The increasing antibiotic resistance observed in this study highlights the urgent need for targeted treatment strategies and stricter infection control measures in ICU settings."

Journal • Infectious Disease • Nephrology

Impact of Parenteral Ceftiofur on Developmental Dynamics of Early Life Fecal Microbiota and Antibiotic Resistome in Neonatal Lambs. (PubMed, Antibiotics (Basel)) - "Unlike the control group, CCFA-treated lambs had core microbes potentially carrying multiple antibiotic resistance genes, including those for beta-lactam, fosfomycin, methicillin, and multidrug resistance...While this highlights microbiota stability after short-course antibiotic exposure, the transient disturbance underscores potential risks to early gut health. Importantly, persistent CCFA resistance poses environmental dissemination risks, emphasizing the need for cautious antibiotic use in livestock to mitigate ecological impacts."

Journal • CNS Disorders • Psychiatry

Challenges in the Treatment of Urinary Tract Infections: Antibiotic Resistance Profiles of Escherichia coli Strains Isolated from Young and Elderly Patients in a Southeastern Romanian Hospital. (PubMed, Biomedicines) - " A significant increase in fluoroquinolone resistance was observed, especially for ciprofloxacin (p = 0.02), alongside rising ceftriaxone resistance (p = 0.004), suggesting the spread of ESBL-producing strains. Resistance to trimethoprim/sulfamethoxazole, ampicillin, and amoxicillin/clavulanic acid remained high, limiting their empirical use...Carbapenems remain effective for severe infections, while nitrofurantoin and fosfomycin are reliable first-line options for uncomplicated UTIs. Continuous AMR surveillance is essential to optimize treatment and curb multidrug-resistant strains."

Journal • Infectious Disease • Nephrology • Novel Coronavirus Disease

Emerging Concepts for the Treatment of Biofilm-Associated Bone and Joint Infections with IV Fosfomycin: A Literature Review. (PubMed, Microorganisms) - "Data from several in vitro and animal models of infection demonstrated that FOS, especially in combination with other antibiotics, is effective against biofilms of (methicillin-resistant) Staphylococcus spp., (vancomycin-resistant) Enterococcus spp., carbapenem-resistant and extended-spectrum beta-lactamase-producing Enterobacterales, and MDR Pseudomonas aeruginosa. FOS exhibits good and fast penetration into bone tissue and is generally well tolerated, with only a few adverse drug reactions, such as gastrointestinal disorders and electrolyte imbalances. Collectively, the data indicate that FOS is a valuable option as part of combination regimens for the treatment of BJIs caused by both GP and GN bacteria."

Journal • Review • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Inflammation • Musculoskeletal Diseases • Orthopedics • Pediatrics • Pneumonia

Detection of rare β-lactamase bla SCO-1 from a Klebsiella pneumoniae high-risk clone in Peru. (PubMed, JAC Antimicrob Resist) - "Susceptibility to amoxicillin/clavulanic acid, amoxicillin/sulbactam, piperacillin/tazobactam, aztreonam, ceftriaxone, cefotaxime, ceftazidime, ceftazidime/avibactam, cefepime, imipenem, meropenem, ciprofloxacin, trimethoprim/sulfamethoxazole, gentamicin, amikacin and tigecycline was determined using the Kirby-Bauer disc diffusion method...Illumina WGS showed the presence of bla SCO-1 and bla OXA-1, bla SHV-28, bla TEM-1, bla CTX-M-15, as well as genes associated with resistance to quinolones, fosfomycin, aminoglycosides, sulphonamides, trimethoprim and phenicols...Phylogenetic relationships were established by comparisons with 19 K. pneumoniae genomes carrying bla SCO-1 from other countries in the Americas, revealing at least three different clades. This study highlights the importance of genomic surveillance of uncommon antimicrobial resistance genes such as bla SCO-1, which might contribute to further antimicrobial resistance levels in this country."

Journal • Infectious Disease • Pneumonia

In vitro activity of ceftazidime- avibactam and ceftolozane- tazobactam against clinical isolates of enterobacteriaceae and pseudomonas æruginosa: results from a trauma center and burn unit in tunisia (PubMed, Ann Burns Fire Disasters) - "CZA proved to be the second most sensitive molecule among all tested antibiotics, following fosfomycin...These antibiotics ranked as the second and third most active beta-lactams after aztreonam...However, CZA remains a salvage therapy for infections caused by carbapenem-resistant organisms, and its use should be considered only after documentation and in the absence of other alternatives among β-lactams. For P. aeruginosa, CZA currently represents the most active β-lactam against CAZ-R strains and the second most active molecule overall, including those producing carbapenemases."

Journal • Preclinical • Critical care • Infectious Disease • Mood Disorders • Pneumonia

UNCOMMON PATHOGEN, SEVERE OUTCOME: CASE REPORT OF LATE-ONSET MENINGITIS DUE TO SERRATIA MARCESCENS IN PRETERM NEONATE (ESPID 2025) - "Meropenem, Fosfomycin and Amikacin were started immediately, adapted to antibiogram. Learning Points/Discussion Serratia marcescens meningitis in newborns is a life-threatening condition that requires prompt diagnosis and aggressive treatment. Despite advances in neonatal care and antibiotic therapy, it remains a significant cause of morbidity and mortality in infected newborns, emphasizing the need for rigorous infection control measures in hospital settings."

Case report • Clinical • Prematurity • Infectious Disease • Septic Shock • CRP

DISSEMINATED OSTEOMYELITIS CAUSED BY MULTIDRUG-RESISTANT ESBL ENTEROBACTERIACEAE IN A PAEDIATRIC SICKLE CELL PATIENT: A CASE REPORT (ESPID 2025) - "High dose continuous IV meropenem was initiated, along with frequent surgical drainages...Adjunctive antibiotic treatment with tigecycline was started and later changed to fosfomycin due to side effects...Conclusions/Learning Points This case highlights the importance of perseverance and comprehensive care in managing complex osteomyelitis in SCD patients. It also underscores the therapeutic and pharmacological challenges in treating bone infections caused by ESBL-producing Enterobacteriacae."

Case report • Clinical • Infectious Disease

TWO CASES OF SEVERE PANTON-VALENTINE LEUKOCIDIN-PRODUCING METHICILLIN SENSITIVE STAPHYLOCOCCUS AUREUS BACTEREMIA WITH MULTIORGAN COMPLICATIONS. (ESPID 2025) - "Antibiotic therapy was changed to cefazolin plus linezolid, then daptomycin plus fosfomycin for 6 weeks in total, followed by a cycle of intravenous dalbavancin. He was treated with cefazolin and linezolid, followed by amoxicillin-clavulanate and rifampicin, for 5 months in total, followed by two dalbavancin infusions, as a bridge to surgery. Learning Points/Discussion These cases highlight that PVL-producing SA bacteremia can lead to complex multiorgan evolution, requiring targeted therapy, multidisciplinary management, and long-term follow-up."

Clinical • Infectious Disease

IN VITRO SUSCEPTIBILITY TESTING OF FOSFOMYCIN AGAINST GRAM-NEGATIVE BACTERIA (ESPID 2025) - "Phoenix showed an acceptable major error rate (< 3%), which means that a 'resistant' result produced by this method is probably true and requires no further testing. However, agar dilution remains to be the only method that can reliably assign a 'susceptible' result for fosfomycin."

Gram negative • Preclinical • Infectious Disease

EFFECTIVENESS AND SAFETY OF INTRAVENOUS FOSFOMYCIN IN TREATING MULTI-DRUG RESISTANT INFECTIONS IN PAEDIATRIC PATIENTS: A RETROSPECTIVE STUDY (ESPID 2025) - "Conclusions/Learning Points Despite the high complexity of our cohort, IV fosfomycin demonstrated both effectiveness and safety in managing difficult-to-treat infections in a vulnerable paediatric population. Its potential role as a rescue therapy for infections resistant to standard treatments should be considered in appropriate clinical contexts."

Retrospective data • Human Immunodeficiency Virus • Infectious Disease

PROLONGED AND REFRACTORY BACTEREMIA IN A PEDIATRIC PATIENT: A DIAGNOSTIC AND THERAPEUTIC CHALLENGE (ESPID 2025) - "Initial combination therapy with meropenem and colistin failed to resolve bacteremia, leading to surgical intervention with cholecystectomy and extended antimicrobial regimens including fosfomycin, ciprofloxacin, and amikacin...After 347 days of meropenem, 205 days of fosfomycin, and 48 days of ceftazidime-avibactam, the patient achieved resolution of bacteremia and was discharged in good condition with monthly IFN-γ and IVIG therapy. Key Learning Points Persistent and refractory Salmonella bacteremia should prompt evaluation for underlying immunodeficiencies, such as IL12 receptor defects, to guide tailored immunomodulatory therapy. Multimodal management, including prolonged antimicrobial therapy, surgical intervention, and immunotherapy, is critical in treating complex cases of disseminated Salmonella infection."

Clinical • IO biomarker • Infectious Disease • IFNG • IL12A

WHEN NO CLEAR GUIDELINE EXISTS: A RARE AND DIFFICULT TO TREAT INFECTION IN AN IMMUNOCOMPROMISED HOST. (ESPID 2025) - "Shortly after stopping ciprofloxacin, and while still treated with ceftazidime, the patient relapsed...Antibiotic therapy was changed for a combination of ceftolozane-tazobactam, ciprofloxacin and fosfomycin...Therapeutic drug monitoring, both in plasma and CSF, might help to optimize CSF concentration of these antibiotics. Optimal duration of therapy is not clear but should be guided by clinical improvement and repeat CSF culture and PCR."

Infectious Disease

Fosfomycin for the treatment of patients with bacterial prostatitis: a systematic review. (PubMed, Eur J Clin Microbiol Infect Dis) - "Fosfomycin could be valuable in the treatment of patients with bacterial prostatitis when there are no other antibiotic options. Due to the limited available published clinical data, a more rigorous evaluation of its effectiveness and safety in this population is needed."

Journal • Review • Infectious Disease

Molecular Characterization of Escherichia coli Causing Community-Acquired Urinary Tract Infections in a Suburban Area in West Bengal, India: Dispersal of Multidrug-Resistant Epidemic ST131 Clone Carrying CTX-M-1. (PubMed, Curr Microbiol) - "Fosfomycin remained 100% effective as an empiric drug, followed by nitrofurantoin (> 75%), aminoglycosides (> 65%), and co-trimoxazole (> 50%). Multidrug-resistant (MDR) was frequent (> 75%), with  70%) mostly carrying CTX-M-15 and TEM-1 (> 50%), which declined in the presence of OXA-1 (> 20%)...ESBL-producing isolates were largely clonally related. This maiden molecular study reveals the infiltration of MDR epidemic clones in a suburban community in eastern India, guiding genomic surveillance for strategic management of AMR at the national level."

Journal • Infectious Disease • Nephrology

Shoulder prosthetic joint infection due to Pseudomonas aeruginosa and carbapenem-resistant Acinetobacter baumannii treated with ciprofloxacin, minocycline and continuous infusion fosfomycin as OPAT regimen: a case report. (PubMed, JAC Antimicrob Resist) - No abstract available

Journal • Infectious Disease

Antimicrobial resistance and genetic diversity of Escherichia coli isolated from marine bivalves. (PubMed, Braz J Microbiol) - "All isolates were sensitive to cefoxitin, imipenem, meropenem, and fosfomycin. The presence of ESBL-producing strains, AMR genes, and diverse plasmid replicons highlights the role of marine environments in AMR dissemination. Continuous AMR surveillance in marine ecosystems is crucial to mitigate public health risks linked to seafood consumption."

Journal